San Francisco Bay Area biotech stories.
Tuesday, August 23, 2011
Vivus to raise $45M in stock sale
Drug developer Vivus made a deal with institutional investors, who agreed to buy 6.889 million shares at $6.65 per share. The company will net a little more than $45 million after expenses of about $562,000.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)